Home > Secukinumab: a new management option for paediatric severe psoriasis

Secukinumab: a new management option for paediatric severe psoriasis

Presented By
Prof. Christine Bodemer, Necker–Enfants Malades Hospital, France

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
EADV 2020
A new option for the management of paediatric severe chronic plaque psoriasis has just emerged with the approval of secukinumab by the European Commission (EC) for the treatment of paediatric moderate-to-severe chronic plaque psoriasis [1]. Until now, there have been limited treatment options for this condition; off-label regimens are frequently utilised with suboptimal results. Secukinumab is a fully human monoclonal antibody that inhibits interleukin (IL)-17, thus disrupting one of the key cytokines involved in the inflammatory pathway which leads to the formation of psoriatic plaques. Prof. Christine Bodemer (Necker–Enfants Malades Hospital, France) reviewed the results to date of a phase 3, randomised, double-blind trial at the EADV Virtual Congress [2]. The 162 subjects between the age of 6 and 18 were randomised to 1 of 4 treatment arms: low-dose secukinumab, high-dose secukinumab, ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on